Tiziana Life Sciences Ltd (TLSA)
Market: NASD |
Currency: USD
Address: 14/15 Conduit Street
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Show more
📈 Tiziana Life Sciences Ltd Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2020 |
- |
$2.499000 |
- |
2020-07-31 |
- |
Stock split |
|
Total Amount for 2020: $2.499000 |
| 2019 |
- |
$2.000000 |
- |
2019-10-29 |
- |
Stock split |
|
Total Amount for 2019: $2.000000 |
📅 Earnings & EPS History for Tiziana Life Sciences Ltd
| Date | Reported EPS |
|---|
| 2025-10-13 (estimated upcoming) | - |
| 2025-06-23 (estimated upcoming) | - |
| 2025-05-08 | - |
| 2023-04-26 | - |
| 2021-09-24 | - |
| 2021-05-17 | - |
| 2020-09-30 | - |
| 2020-09-30 | - |
| 2020-06-17 | - |
| 2019-09-30 | - |
| 2019-04-04 | - |
| 2018-11-21 | - |
📰 Related News & Research
No related articles found for "tiziana life".
